Competition Between Biosimilars and Patented Biologics: Learning from European and Japanese Experience

PharmacoEconomics

Volumn 34, Issue 11, 2016, Pages 1173-1186

  Bocquet, François ^a,b,c   Loubière, Anaïs ^c   Fusier, Isabelle ^c   Cordonnier, Anne Laure ^c   Paubel, Pascal ^a,b,c  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSERM   (France)

^c ASSISTANCE PUBLIQUE HÔPITAUX DE PARIS   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOSIMILAR AGENT; ERYTHROPOIETIN; GENERIC DRUG; GRANULOCYTE COLONY STIMULATING FACTOR; BIOLOGICAL PRODUCT;

ARTICLE; DATA PROCESSING; DRUG COST; DRUG MARKETING; DRUG USE; ECONOMIC MODEL; EUROPE; HEALTH CARE POLICY; HOSPITAL; HUMAN; JAPAN; PATENT; PRIORITY JOURNAL; DRUG DESIGN; DRUG INDUSTRY; ECONOMIC ASPECT; ECONOMICS; STATISTICAL MODEL;

BIOLOGICAL PRODUCTS; BIOSIMILAR PHARMACEUTICALS; DRUG DESIGN; DRUG INDUSTRY; DRUGS, GENERIC; ECONOMIC COMPETITION; ERYTHROPOIETIN; EUROPE; GRANULOCYTE COLONY-STIMULATING FACTOR; HUMANS; JAPAN; LINEAR MODELS; MODELS, ECONOMIC; PATENTS AS TOPIC;

EID: 84978134347     PISSN: 11707690     EISSN: 11792027     Source Type: Journal    
DOI: 10.1007/s40273-016-0428-6     Document Type: Article

References (43)

1. Financing of Social Security Act for 2014 of 23 December 2013 [in French], Art 47, loi no. 2013–1203. J Off République Française. 2013;298:21034.
2. Directive 2004/27/EC of the European Parliament and of the Council of 31st March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Off J Eur Union L. 136:34–57. http://eur-lex.europa.eu/en/index.htm. Accessed 15 Dec 2015.
3. Rickwood S, Di Biase S. Searching for terra firma in the biosimilars and non-original biologics market—insights for the coming decade of change. IMS Health Whitepaper, 2013. http://www.imshealth.com/deployedfiles/imshealth/Global/Content/Healthcare/Life%20Sciences%20Solutions/Generics/IMSH_Biosimilars_WP.pdf. Accessed 14 Dec 2015.
4. Shaping the biosimilars opportunity: a global perspective on the evolving biosimilars landscape. IMS Health Whitepaper. 2011. http://www.imshealth.com/ims/Global/Content/Home%20Page%20Content/IMS%20News/Biosimilars_Whitepaper.pdf. Accessed 14 Dec 2015.
5. DeVries JH, Gough SC, Kiljanski J, et al. Biosimilar insulins: a European perspective. Diabetes Obes Metab. 2015;17(5):445–51.
6. Falit BP, Singh SC, Brennan TA. Biosimilar competition in the United States: statutory incentives, payers, and pharmacy benefit managers. Health Aff (Millwood). 2015;34(2):294–301.
7. FDA News Release—FDA approves first biosimilar product Zarxio, March 6, 2015. US Food and Drug Administration. 2015. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm436648.htm. Accessed 14 Dec 2015.
8. Grabowski HG, Ridley DB, Schulman KA. Entry and competition in generic biologicals. Manag Decis Econ. 2007;28:439–51.
9. Bocquet F, Paubel P, Fusier I, et al. Biosimilar Granulocyte-Stimulating factor uptakes in the EU-5 Markets: a descriptive analysis. Appl Health Econ Health Policy. 2014;12:315–26.
10. Bocquet F, Paubel P, Fusier I, et al. Biosimilar versus patented erythropoietins: learning from 5 years of European and Japanese experience. Appl Health Econ Health Policy. 2015;13:47–59.
11. IMS Health. MIDAS database. La Défense: IMS Health; 2014.
12. Abraham I, MacDonald K. Clinical efficacy and safety of HX575, a biosimilar recombinant human erythropoietin, in the management of anemia. Biosimilars. 2012;2:13–25.
13. WHO Collaborating Centre for Drug Statistics Methodology. 2009. http://www.whocc.no/ddd/definition_and_general_considera. Accessed 14 Dec 2015.
14. Eurostat. Population and population change statistics, 2015. http://ec.europa.eu/eurostat/statistics-explained/index.php/Population_and_population_change_statistics#EU-28_population_continues_to_grow. Accessed 15 Dec 2015.
15. The World Bank, data, population (total). 2015. http://data.worldbank.org/indicator/SP.POP.TOTL. Accessed 15 Dec 2015.
16. WHO National Medicine Price Sources. http://www.who.int/medicines/areas/access/sources_prices/national_medicine_price_sources.pdf. Accessed 14 Dec 2015.
17. IMS. Biosimilar accessible market: size and biosimilar penetration, prepared for EFPIA-EGA-EuropaBio. April 2012. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_imsstudy_en.pdf. Accessed 15 Dec 2015.
18. Jakovljevic MB, Nakazono S, Ogura S. Contemporary generic market in Japan: key conditions to successful evolution. Expert Rev Pharmacoecon Outcomes Res. 2014;14(2):181–94.
19. The biosimilar name debate. What’s at stake for public health. Generics Biosimilars Initiat J. 2014;3(1):10–2.
20. Grabowski H, Guha R, Salgado M. Biosimilar competition: lessons from Europe. Nat Rev. 2014;13(2):99–100s.
21. Karouby D, Vallet C, Bocquet F, et al. Comparative study of the cost of erythropoietic factors, original medicines and biosimilars in French care facilities. DSL-005. Eur J Hosp Pharm. 2013;20(Suppl 1):A1–238.
22. Power DA. Licensing and prescribing biosimilars in Australia. Generics Biosimilars Initiat J. 2013;2(3):152–4.
23. ® (epoetin alfa), European Medicines Agency (EMA). 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Scientific_Discussion/human/000725/WC500053615.pdf. Accessed 14 Dec 2015.
24. ® (filgrastim), European Medicines Agency (EMA), 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000917/WC500046528.pdf. Accessed 14 Dec 2015.
25. ® (filgrastim), European Medicines Agency (EMA), 2014. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_Public_assessment_report/human/000825/WC500047793.pdf. Accessed 14 Dec 2015.
26. ® (epoetin alfa). http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000725/WC500053680.pdf. Accessed 14 Dec 2015.
27. Safety study for subcutaneous epoetin alfa biosimilar Binocrit / Epoetin alfa Hexal / Abseamed suspended. Generics Biosimilars Initiative Online; Oct. 2009. http://www.gabionline.net/Biosimilars/News/Safety-study-for-subcutaneous-epoetin-alfa-biosimilar-Binocrit-Epoetin-alfa-Hexal-Abseamed-suspended. Accessed 15 Dec 2015.
28. Schellekens H, Jiscoot W. Eprex-associated pure red cell aplasia and leachates. Nat Biotechnol. 2006;24(6):613–4.
29. Hermeling S, Schellekens H, Crommelin DJ, et al. Micelle-associated protein in epoietin formulations: a risk factor for immunogenicity? Pharm Res. 2003;20:1903–7.
30. Farfan-Portet M-I, Gerkens S, Lepage-Nefkens I. Are biosimilars the next tool to guarantee cost-containment for pharmaceutical expenditures? Eur J Health Econ. 2014;15:223–8.
31. Grabowski H, Long G, Mortimer R. Implementation of the biosimilar pathway: economic and policy issues, Seton hall law review. 2011;41(2). Article 2. http://erepository.law.shu.edu/shlr/vol41/iss2/2. Accessed 15 Dec 2015.
32. Declerck P, Simoens S. A European perspective on the market accessibility of biosimilars. Biosimilars. 2012;2:33–40.
33. Rovira J, Espin J, Garcia L et al. The impact of biosimilars’ entry in the EU market. Andalusian School of Public Health Report for the European Commission (Directorate-General for Enterprise and Industry). 2011. http://ec.europa.eu/enterprise/sectors/healthcare/files/docs/biosimilars_market_012011_en.pdf. Accessed 15 Dec 2015.
34. Glaeske G, Schicktanz C, Barmer GEK. Arzneimittel report 2011 Bremen: Universität Bremen. Abteilung für Gesundheitsökonomie, Gesundheitspolitik und Versorgungsforschung, 2011 [in German]. http://www.zes.uni-bremen.de/uploads/News/2011/110713_Kurzfassung.pdf. Accessed 15 Dec 2015.
35. Matusewicz W, Godman B, Pedersen HB, Fürst J, Gulbinovic J, Mack A, et al. Improving the managed introduction of new medicines: sharing experiences to aid authorities across Europe. Expert Rev Pharmacoecon Outcomes Res. 2015;15(5):755–8.
36. Brodszky V, Rencz F, Péntek M, Baji P, Lakatos PL, Gulácsi L. A budget impact model for biosimilar infliximab in Crohn’s disease in Bulgaria, the Czech Republic, Hungary, Poland, Romania, and Slovakia. Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119–25.
37. Mack A. Norway, biosimilars in different funding systems. What works? GaBI J. 2015;4(2):90–2.
38. Vogler S, Zimmermann N, Habl C, Piessnegger J, Bucsics A. Discounts and rebates granted to public payers for medicines in European countries. South Med Review. 2012;5(1):38–46.
39. Vogler S, Zimmermann N, Habl C, Mazag J. The role of discounts and loss leaders in medicine procurement in Austrian hospitals—a primary survey of official and actual medicine prices. Cost Eff Resour Alloc. 2013;11(1):15.
40. Godman B. Health authority perspective on biosimilars. GaBI J. 2013;2(1):10–1.
41. Curto S, Ghislandia S, van de Voorena K, et al. Regional tenders on biosimilars in Italy: an empirical analysis of awarded prices. Health Policy. 2014;116:182–7.
42. Mestre-Ferrandiz J, Towse A, Berdud M. Biosimilars: How can payers get long-term savings? Pharmacoeconomics. 2016;34(6):609–16.
43. Dylst P, Vulto A, Simoens S. Barriers to the uptake of biosimilars and possible solutions: a Belgian case study. Pharmacoeconomics. 2014;32(7):681–91.